Compare Eli Lilly And Co (LLY) vs ProShares UltraPro Short QQQ ETF (SQQQ) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Eli Lilly And Co vs ProShares UltraPro Short QQQ ETF — how do they compare? Eli Lilly And Co trades at $1,161.66 (market cap $1.02T), while ProShares UltraPro Short QQQ ETF trades at $40.75. The key difference: Eli Lilly And Co pays a 0.6% dividend while ProShares UltraPro Short QQQ ETF pays none. Which is the better fit depends on your goals.
| LLY | SQQQ | |
|---|---|---|
Market Cap | $1.02T | — |
Sector | Health | Leveraged / Inverse |
52-Week High | $1.24K | $97.60 |
52-Week Low | $625.65 | $36.31 |
Enterprise Value | $1.06T | — |
Dividend Yield | 0.6% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Eli Lilly (LLY) trades at $1,150.86, down 2.39% on the day, with a bullish technical signal from moving averages and strong fundamental performance. The company reported robust earnings beats in recent quarters, with Q1 2026 EPS of $8.55 exceeding expectations by 23%. Revenue surged to $65.18 billion in 2025, driving a net income margin of 34.99%. Recent news highlights LLY's $2.8 billion acquisition of AtaiBeckley to expand its neuroscience pipeline, signaling strategic growth in mental health treatments.
Outlook remains positive with analyst consensus price target of $1,380 implying 20% upside, supported by 73% buy ratings. Key risks include high valuation multiples (P/E 41.89) and rising debt levels, though operating cash flow growth to $16.81 billion in 2025 provides financial flexibility. Investors should monitor Q2 2026 earnings on August 5 for continued execution on weight-loss drug demand and integration of recent acquisitions.
SQQQ trades at $42.68, down 0.26% with a bullish technical signal from moving averages but neutral oscillators. The ETF faces fundamental challenges as a leveraged short product with no traditional valuation metrics. Recent news highlights SQQQ's role as a tactical hedging tool against QQQ, though articles warn of significant long-term value erosion due to daily resets.
Outlook remains high-risk with SQQQ suitable only for sophisticated investors seeking short-term Nasdaq 100 downside protection. The primary risk is structural decay from daily rebalancing, making long-term holding detrimental. Analyst sentiment is cautious, emphasizing timing-dependent utility rather than investment merit.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Eli Lilly And Co
Eli Lilly is a drug firm with a focus on neuroscience, endocrinology, cancer, and immunology. Lilly's key products include Verzenio for cancer
Read more on LLY →About ProShares UltraPro Short QQQ ETF
SQQQ is a leveraged inverse ETF that seeks daily investment results, before fees and expenses, that correspond to three times the inverse (-3x) of the daily performance of the Nasdaq-100 Index. It is a tactical trading tool designed for sophisticated investors to profit from or hedge against declines in large-cap technology and growth stocks. Due to its daily reset and the effects of compounding, it is intended for short-term use and carries significant risk if held during periods of high market volatility.
Read more on SQQQ →
